Tryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan
San Diego, California–(Newsfile Corp. – July 21, 2021) – Tryp Therapeutics (CNSX:TRYP.CN) (OTCQB:TRYPF) (“Tryp”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today its plans to conduct a Phase 2a clinical trial with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University […]
Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training
London, UK – 21 July 2021 COMPASS Pathways plc (Nasdaq:CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed Danielle Schlosser PhD as Senior Vice-President, Clinical Innovation. Dr Schlosser will lead COMPASS’s Therapy Research and Training team, bringing her clinical experience in […]
Small Pharma Establishes Psychedelic-assisted Therapy Training Program
Training program established ahead of Phase II clinical trials Phase IIa due to start imminently and Phase IIb expected to commence in 2022 LONDON , July 21, 2021 /PRNewswire/ — Small Pharma Inc. (TSXV:DMT.VN) (the ” Company ” or ” Small Pharma “), a neuropharmaceutical company focused on psychedelic-assisted N,N-dimethyltryptamine (” DMT “) therapies, has launched a training program to educate psychologists on the process required for […]
Core One Labs’ Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment
Core One Labs Inc. (CNSX:COOL.CN) (OTC:CLABD) (Frankfurt: LD6, WKN:A3CSSU) (the “Company”) is excited to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has protected its breakthrough ketamine psychedelic drug formulation for the treatment of Depression and is set to begin further development. The formulation of Akome’s breakthrough depression treatment, also known as AKO003, […]
